Publications by authors named "O Yu Fedorenko"
Metabolic syndrome (MetS) is common among schizophrenia patients, and one of MetS's causes may be an imbalance in nitric oxide regulation. In this study, we examined associations of three polymorphic variants of the nitric oxide synthase 1 adapter protein () gene with MetS in schizophrenia. NOS1AP regulates neuronal nitric oxide synthase, which controls intracellular calcium levels and may influence insulin secretion.
View Article and Find Full Text PDFWhite adipose tissue (WAT) requires extracellular Ca2+ influx for lipolysis, differentiation, and expansion. This partly occurs via plasma membrane Ca2+ voltage-dependent channels (CaVs). However, WFA exists in different depots whose function varies with age, sex, and location.
View Article and Find Full Text PDFArticle Synopsis
- - The study explores how genetic variations influencing the glutamatergic neurotransmitter system impact the development and clinical symptoms of schizophrenia in 805 Russian patients from Siberia.
- - Three specific gene variants (rs11644461, rs8057394, rs7313149) are linked to a particular type of schizophrenia, with the rs8057394*G allele identified as a risk factor for this type.
- - Additionally, another variant (rs62126236) shows a protective effect against negative symptoms, while overall symptom severity is significantly associated with yet another variant (rs9788936), indicating the role of genetic factors in schizophrenia's clinical diversity.
The dopamine, serotonin and glutamate systems are jointly involved in the pathogenesis and pharmacotherapy of schizophrenia. We formulated a hypothesis that polymorphic variants of the GRIN2A, GRM3, and GRM7 genes may be associated with the development of hyperprolactinemia in patients with schizophrenia taking conventional and atypical antipsychotics as basic treatment. 432 Caucasian patients diagnosed with schizophrenia were examined.
View Article and Find Full Text PDFArticle Synopsis
- Metabolic syndrome is common among schizophrenia patients on long-term antipsychotic treatment, which can result from the effects of dopamine D2 receptors.
- The study analyzed 517 schizophrenia patients in Siberia, focusing on two specific genetic variations in the DRD2 gene and their link to metabolic syndrome.
- Findings suggest that a particular variation (rs1799732) is associated with drug-induced metabolic syndrome in women, pointing to the potential for targeted genetic treatments to improve patient outcomes.